Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.

Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe.
Euro Surveill. 2017 Feb 16;22(7):
Authors: Kissling E, Rondy M, I-MOVE/I-MOVE+ study team
Abstract
We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0-14, 15-64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65-79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).
PMID: 28230524 [PubMed - in process]

Source: Euro Surveill - February 15, 2017 Category: Infectious Diseases Authors: Kissling E, Rondy M, I-MOVE/I-MOVE+ study team Tags: Euro Surveill Source Type: research